ArticleiScience2026
Pediatric RSV-associated lower respiratory tract infection burden in G20 countries in 2023.
Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Respiratory syncytial virus (RSV) is a leading cause of childhood lower respiratory infections, but updated G20 burden estimates are lacking. Using the Global Burden of Disease 2023 database, we analyzed deaths and disability-adjusted life years (DALYs) for RSV-associated lower respiratory infections in children aged 0-14 years across G20 members from 1990 to 2023, with stratification by sex, age, and country. In 2023, an estimated 5,373 deaths and 483,162 DALYs occurred, with mortality and DALY rates having declined by ∼5.5% annually since 1990. The COVID-19 pandemic drove burden to a historic low in 2021, but a marked rebound followed in 2022-2023, though rates remained below pre-pandemic levels. Infants aged <1 year bore the heaviest burden (mortality 8.688 per 100,000), and India ranked highest, whereas Australia ranked lowest. Burden strongly correlated inversely with Sociodemographic Index. These findings highlight the need for precision prevention, targeting the youngest children and lower-resource G20 members.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.